STAT

Public service loan forgiveness can help fix the shortage of primary care and rural physicians

Tweaking the Public Service Loan Forgiveness Program could ease medical students' debt and help solve the shortage of primary care and rural doctors.
Strategic changes to the Public Service Loan Forgiveness Program could help increase the number of doctors working in rural, underserved, or impoverished areas.

The medical profession seems caught in a “Catch-22”: The growing cost of medical education is generating crushing levels of debt. This debt, in turn, is contributing to a doctor shortage and discouraging students from filling our growing needs for primary care physicians serving in poor, rural, and other underserved areas.

There is hope, however, as students return to campus. A single solution involving the Public Service Loan Forgiveness Program can solve both problems if educators and government can come together and transform debt relief into an instrument for improving health care.

The numbers are stark and dispiriting. Seventy-six percent of. Their average debt is $190,000. Interest can push the repayment total well over $400,000. That is an especially troubling prospect for young doctors who typically begin their careers in low-paying residency programs that generally last three to five years.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Senate Probe Into Novo Pricing, A New UTI Antibiotic, And More
The U.S. Senate health committee is investigating the prices Novo Nordisk charges for its blockbuster medications Ozempic and Wegovy.

Related Books & Audiobooks